Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?

İnal, Ali; Kaplan, Mehmet Ali; Küçüköner, Mehmet; Urakçı, Zuhat; Kılınç, Faruk; Işıkdoğan, Abdurrahman

doi:10.1016/j.rppneu.2013.09.001

Cited by 31 publications

(39 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After further evaluating the articles identified, 12 articles with a total of 15,180 lung cancer patients stratifying by DM status were included in the meta-analysis. 9–11,18–26 …”

Section: Resultsmentioning

confidence: 99%

“…A total of 20 cohorts from 12 studies were included, which were published between 2003 and 2014. Of the 20 cohorts, 16 cohorts 9–11,18,19,21–26 with a total of 14,643 lung cancer cases investigated the OS and 4 studies 9,11,20,22 with a total of 1711 lung cancer patients investigated the PFS. The outcomes of all the 20 cohorts were adjusted for several potential confounders, including age, gender, smoking status, performance status, body mass index, and so on.…”

Section: Resultsmentioning

confidence: 99%

“…8 However, evidence on the correlation between DM and outcome of lung cancer is conflicting and indefinite. 9–11 To derive a more precise estimate of the prognostic value of DM in lung cancer patients, we performed this meta-analysis of eligible published articles according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 12 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Effect of Diabetes Mellitus on Lung Cancer Prognosis

et al. 2016

View full text Add to dashboard Cite

Previous studies suggested that diabetes mellitus (DM) was associated with risk and mortality of cancer, but studies investigating the correlation between DM and lung cancer prognosis remain controversial. Herein, a meta-analysis was performed to derive a more precise estimate of the prognostic role of DM in lung cancer.Medline and Embase were searched for eligible articles from inception to October 25, 2015. The pooled hazard ratio (HR) with its 95% confidence interval (95% CI) was calculated to evaluate the correlation between DM and lung cancer prognosis. Subgroup meta-analysis was performed based on the histology and the treatment methods.A total of 20 cohort studies from 12 articles were included in the meta-analysis. Also, 16 studies investigated the overall survival (OS) and 4 studies investigated the progression-free survival (PFS). DM was significantly associated with the inferior OS of lung cancer with the pooled HR 1.28 (95% CI: 1.10–1.49, P = .001). The association was prominent in the nonsmall cell lung cancer (NSCLC) subgroup (HR 1.35, 95%CI: 1.14–1.60, P = .002), whereas the association was not significant in the small cell lung cancer (SCLC) subgroup (HR 1.33, 95% CI: 0.87–2.03, P = .18). When NSCLC patients were further stratified by treatment methods, DM had more influence on the surgically treated subgroup than the nonsurgically treated subgroup. There was no obvious evidence for publication bias by Begg's and Egger's test.The results of this meta-analysis exhibit an association of DM with inferior prognosis amongst lung cancer patients, especially the surgically treated NSCLC patients. Given the small number of studies included in this meta-analysis, the present conclusion should be consolidated with more high-quality prospective cohort studies or randomized controlled trials.

show abstract

“…After further evaluating the articles identified, 12 articles with a total of 15,180 lung cancer patients stratifying by DM status were included in the meta-analysis. 9–11,18–26 …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Diabetes Mellitus on Lung Cancer Prognosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Though controversial, there has been suggestion in the literature that cancer patients with diabetes have worse outcomes compared with cancer patients without diabetes [70–72]. In a retrospective study of 442 patients with advanced NSCLC treated with platinum doublet therapy in the first-line setting, baseline diabetes was associated with inferior OS and PFS [72].…”

Section: Nab-paclitaxel As First-line Therapy For Advanced Nsclcmentioning

confidence: 99%

“…In a retrospective study of 442 patients with advanced NSCLC treated with platinum doublet therapy in the first-line setting, baseline diabetes was associated with inferior OS and PFS [72]. This may be due in part to difficulty in treatment delivery in this patient population due to the treatment-related toxicities which may be more pronounced in the diabetic lung cancer population.…”

Section: Nab-paclitaxel As First-line Therapy For Advanced Nsclcmentioning

confidence: 99%

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Villaruz

Socinski

2016

European Journal of Cancer

View full text Add to dashboard Cite

Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. This approval was based on the results of a phase III clinical trial showing superior response rates compared with solvent-based paclitaxel in combination with carboplatin. This review will focus on the early development and clinical data to date supporting the use of nab-paclitaxel in advanced NSCLC. The clinical question central to this review is whether nab-paclitaxel has a place in the current therapeutic landscape of advanced NSCLC.

show abstract

Poor glycemic control might compromise the efficacy of chemotherapy in non‐small cell lung cancer patients with diabetes mellitus

Zeng

Cheng

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Background: Previous studies indicated that type 2 diabetes mellitus (T2DM) is related to an increased lung cancer risk, but its role in the prognosis of NSCLC remains conflicting. This study investigated the impact of blood glucose control on the outcomes in NSCLC patients with T2DM treated with platinum-based doublets. Methods: Clinicopathological and survival data from 191 T2DM patients with advanced NSCLC, who received platinum-based chemotherapy, were retrospectively analyzed. Based on the blood glucose conditions during chemotherapy, patients were classified into poor (n = 84) and good control (n = 107) groups. Progression-free survival (PFS) was assessed using the Kaplan-Meier method. Results: The median PFS among patients with good glycemic control [197.0 (95% CI: 136.3-257.7) days] was longer than that among those with poor control [132.0 (95% CI: 112.5-151.5) days] (P = .0003). Further subgroup analysis of lung squamous carcinoma and adenocarcinoma patients showed that the median PFS of the good control group was also significantly longer than that of the poor control group [179.0 (95% CI: 78.4-279.6) days vs 125.0 (95% CI: 110.9-139.1) days, P = .0014;197.0 (95% CI: 124.3-269.7) days vs 154.0 (95% CI: 129.9-178.1) days, P = .0359; respectively]. The incidence rates of side effects were similar among patients with good glycemic control and those with poor glycemic control (all P > .05). Conclusions: Satisfactory glycemic control during platinum-based chemotherapy might provide a survival benefit to T2DM patients with NSCLC. Further studies are warranted to confirm our findings. K E Y W O R D Sglycemic control level, non-small cell lung cancer, platinum-based chemotherapy, progression-free survival, type 2 diabetes mellitus | 903 ZENG Et al.

show abstract

Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?

Cited by 31 publications

References 32 publications

The Effect of Diabetes Mellitus on Lung Cancer Prognosis

The Effect of Diabetes Mellitus on Lung Cancer Prognosis

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Poor glycemic control might compromise the efficacy of chemotherapy in non‐small cell lung cancer patients with diabetes mellitus

Contact Info

Product

Resources

About